Centers for Disease Control and Prevention,National Center for HIV Viral Hepatitis STD and TB Prevention

This information sheet discusses the hepatitis A vaccine. It explains hepatitis A virus infection, its effect on the liver, and its transmission and symptoms, and advises that a vaccine can prevent the disease. The information sheet lists who should get the vaccine and when, who should not get the vaccine or should wait, whether there are any risks or adverse reactions to the vaccine, different types of reactions, and what to do. It describes the National Vaccine Injury Compensation Program and provides sources of further information.

This information sheet discusses treatment for individuals with latent tuberculosis infection (LTBI), with the purpose of this treatment being the reduction of the risk that the infection will progress to TB disease. It explains how the health care provider determines whether the individual with a positive tuberculin skin test (TST) or blood test result is a candidate for treatment of LTBI and how the most effective regimen is chosen; presents LTBI treatment regimens; and describes monitoring during treatment, drug-drug interactions, particularly for HIV-infected patients, and side effects.

This information sheet summarizes the key findings of the new analysis of the CDC’s new estimates of the annual number of new HIV infections in the United States. The new analysis was published in the Morbidity and Mortality Weekly Report of September 12, 2008. The results of the analysis shows that among gay and bisexual men, young African Americans and Whites in their 30s and 40s are most affected, African American women are more affected than women of other races, and men account for the majority of new HIV infection among Hispanics/Latinos.

This report discusses the sexually transmitted disease (STD), chlamydia, which is common among sexually active adolescents and young adults. It explains that although chlamydia may be asymptomatic, it can have serious consequences in females, including infertility; hence, the importance of chlamydia prevention. Screening females aged <25 years is ranked by the National Commission on Prevention Priorities as one of the 10 most beneficial and cost-effective prevention services, but it also is one of the most underutilized.

This report provides a summary of responses from a web-based survey of public health laboratories on volume and type of testing for STDs in the United States in 2007. The survey was conducted in 2008. Responses were received from 61.4 percent (94 of 153) participants. In 2007, 3,290,390 chlamydia tests and 3,157,827 gonorrhea tests were performed in the surveyed laboratories; 89.7 percent of chlamydia tests and 84.4 percent of gonorrhea tests were nucleic acid amplification tests. Over 90 percent of responders reported syphilis testing.

This report describes tests of an analysis of data from five laboratories that used reverse sequence screening during 2006-2010 to identify persons with possible untreated syphilis. Three sites served patient populations with low prevalence of syphilis, and two sites served patient population with high prevalence. The results indicated that among sera reactive on initial screening with an automatable treponemal enzyme and chemiluminescence immunoassays (EIA/CIA), 56.7 percent had a nonreactive rapid plasma regain (RPR) test.

This poster urges anyone who has ever injected drugs to get tested for hepatitis C.

This poster states that hepatitis B is a serious disease spread by sexual contact. It promotes vaccination as a way of preventing the disease.

This poster states that 1 in 12 Asian has chronic Hepatitis B and advises Asian Americans to consult their doctors about getting tested.